Browse treatments

…Background Immune cell engineering has the potential to revolutionize the treatment of many pathol…

…Background Despite advances in immunotherapy, durable patient responses remain a minority. This is partly du…

…r cell types to enhance clinical outcomes, often in the form of multispecific antibody treatments (‘multispecifics’). Many of these multispecifics target the T c…

…Background CAR T cell therapy has had a tremendous impact on the treatment of hematological c…

…ite remarkable results for many patients, the response rate for immunotherapy varies from one patient to the next. While technological advanc…

…hich can necessitate immunosuppression and ICI discontinuation. Fecal microbiota transplantation (FMT) has shown promise in treating irColitis, but concerns aro…

…bial alterations to simulate human susceptibility to irAEs upon anti-PD-1 therapy. 3 4 This model faithfully recapitulates human disease in tissu…

… and accounting for 35% of ICI-related deaths in patients under anti-programmed cell death ligand-1(PD-L1) therapy. 1 Real-world studies have demonstrated higher incidence rates …

…f therapy mechanism of action and identification of response to cancer therapy. We present results from two phase 1 studies sponsored by GE He…

…Background Immunotherapies exhibit class- and target-specific safety challenges, particula…

…lly morbid toxicities, occurring in ~1-8% of patients receiving immunotherapy. Prognostic and predictive biomarkers are lacking. We hypothesi…

…nt predictors of renal IRAEs. As for dermatological IRAEs, only Chemotherapy (p = 0.031) and cancer stage (p=0.006) were significant predict…